AG Eilers

Research

Understanding MYC function

Targeting N-MYC/AURORA for tumor therapy

MYC and Ubiquitin

Group Members

Publications

Latest:

Papadopoulos D*, Ha S*, Fleischhauer D*, Uhl L, Russel TJ, Mikicic I, Schneider K, Brem A, Valanju OR, Cossa Giaocmo, Gallant P, Schuelein-Voelk C, Maric HM, Beli P, Büchel G, Vos SM , Eilers M (2024)  The MCYN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. Mol Cell, doi: 10.1016/j.molcel.2024.04.007

Gaballa A, Gebhardt-Wolf A, Krenz B, Mattavelli G, John M, Cossa G, Andreani S, Schülein-Völk C, Montesinos F, Vidal R, Kastner C, Ade CP, Kneitz B, Gasteiger G, Gallant P, Rosenfeldt M, Riedel A, and Eilers M (2024) PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma. Nat Commun, doi: 10.1038/s41467-024-45760-8

Alborzinia H, Chen Z, Yildiz U, Freitas FP, Vogel F, Varga JP, Batani J, Bartenhagen C, Schmitz W, Büchel G, Michalke B, Zheng J, Meierjohann S,  Girardi E, Espinet E, Florez AF, dos Santos AF, Aroua N, Cheytan T, Haenlin J, Schlicker L, da Silva X, Nishida T, Przybylla A, Zeisberger P, Superti-Furga G, Eilers M, Conrad M, Fabiano M, Schweizer U, Fischer M, Schulze A, Trumpp A,  Friedmann Angeli JP, LRP8-Mediated Selenocysteine Uptake is a Targetable Vulnerability in MYCN-Amplified Cancers. EMBO Mol Med doi: 10.2139/ssrn.4391015

Solvie D, Baluapuri A, Uhl L, Fleischhauer D, Endres T, Papadopoulos D, Aziba A, Gaballa A, Mikicic I, Isaakova E, Giansanti C, Jansen J, Jungblut M, Klein T, Schulein-Volk C, Maric H, Doose S, Sauer M, Beli P, Rosenwald A, Dobbelstein M, Wolf E, Eilers M (2022) MYC multimers shield stalled replication forks from RNA polymerase. Nature doi: 10.1038/s41586-022-05469-4

Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, Bhattacharya A, Joosten SEP, Da Silva AM, Padrao N, Wellenstein MD, Kersten K, de Boo M, Roorda M, Henneman L, de Bruijn R, Annunziato S, van der Burg E, Drenth AP, Lutz C, Endres T, van de Ven M, Eilers M, Wessels L, de Visser KE, Zwart W, Fehrmann RSN, van Vugt MATM, Jonkers J. (2022) MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun doi: 10.1038/s41467-022-34000-6.

Otto C, Kastner C, Schmidt S, Uttinger K, Baluapuri A, Denk S, Rosenfeldt MT, Rosenwald A, Roehrig F, Ade CP, Schuelein-Voelk C, Diefenbacher ME, Germer CT, Wolf E, Eilers M, Wiegering A (2022) RNA polymerase I inhibition induces terminal differentiation, growth arrest and vulnerability to senolytics in colorectal cancer cells. Mol Oncol doi: 10.1002/1878-0261.13265

Mainz L, Sarhan M, Roth S, Sauer U, Kalogirou C, Eckstein M, Gerhard-Hartmann E, Seibert HD, Voelker HU, Geppert C, Rosenwald A, Eilers M, Schulze A, Diefenbacher M, Rosenfeldt MT (2022) Acute systemic knockdown of Atg7 is lethal and causes pancreatic destruction in shRNA transgenic mice. Autophagy: 1-14. doi: 10.1080/15548627.2022.2052588.

Papadopoulos D, Solvie D, Baluapuri A, Endres, T, Ha S., Herold S, Kalb J, Giansanti C, Schülein-Völk C, Ade CP, Schneider C, Gaballa A, Vos S, Fischer U, Dobbelstein M, Wolf E., Eilers M (2021) MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription‑replication conflicts. Mol Cell doi.org/10.1016/j.molcel.2021.11.002

Narain A, Bhandare P, Adhikari B, Backes S, Eilers M, Dolken L, Schlosser A, Erhard* F, Baluapuri* A, Wolf* E (2021) Targeted protein degradation reveals a direct role of SPT6 in RNAPII elongation and termination. Mol Cell 81: 3110-3127 e14 *corresponding authors

Cossa G, Parua PK, Eilers M, Fisher RP (2021) Protein phosphatases in the RNAPII transcription cycle: erasers, sculptors, gatekeepers, and potential drug targets. Genes Dev 35: 658-676

Roeschert I, Poon E, Henssen AG, Garcia HD, Gatti M, Giansanti C, Jamin Y, Ade CP, Gallant P, Schulein-Volk C, Beli P, Richards M, Rosenfeldt M, Altmeyer M, Anderson J, Eggert A, Dobbelstein M, Bayliss R, Chesler* L, Buchel* G, Eilers* M (2021) Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma. Nat Cancer 2: 312-326 *corresponding authors

Wolpaw AJ, Bayliss R, Buchel G, Dang CV, Eilers M, Gustafson WC, Hansen GH, Jura N, Knapp S, Lemmon MA, Levens D, Maris JM, Marmorstein R, Metallo SJ, Park JR, Penn LZ, Rape M, Roussel MF, Shokat KM, Tansey WP, Verba KA, Vos SM, Weiss WA, Wolf E, Mosse YP (2021) Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Res 81: 1627-1632

Endres T, Solvie D, Heidelberger JB, Andrioletti V, Baluapuri A, Ade CP, Muhar M, Eilers U, Vos SM, Cramer P, Zuber J, Beli P, Popov N, Wolf E, Gallant P, Eilers M (2021) Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters. Mol Cell 81: 830-844 e13

Krenz B, Gebhardt-Wolf A, Ade CP, Gaballa A, Roehrig F, Vendelova E, Baluapuri A, Eilers U, Gallant P, D'Artista L, Wiegering A, Gasteiger G, Rosenfeldt MT, Bauer S, Zender L, Wolf E, Eilers M (2021) MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer Res 81: 4242-4256

Link to all Publications in PubMed